Podcasts

E-Books

Videos

Articles

Clinical

Sophia Z. Humphreys, PharmD, MHA, is the director of System Pharmacy Clinical Services for Providence St. Joseph Health (PSJH), a multistate hospital system based in Renton, Washington. She has nearly 20 years of specialized experience in the pharmaceutical industry and is an expert in pharmacy regulatory compliance, US Pharmacopeia General Chapter <797>/<800> pharmacy regulations, clinical education, long-term care pharmacy service, and pharmaceutical waste management. She has a strong background in strategic planning and project management. Prior to her current position, she served as the PSJH drug information manager.

Sophia Z. Humphreys, PharmD, MHA, explains how biosimilar utilization management can enable health care institutions to put COVID-19–related financial wreckage behind them.

Opinion: Biosimilars Can Aid in Post–COVID-19 Health Care Financial Recovery

Tony Hagen is senior managing editor for The Center for Biosimilars

The “winner-takes-all” tender process for biosimilar procurement in the European Union runs the risk of driving competitors out of the market, authors of a new survey contend. 

Survey: European Union Needs to Fine-tune Its Biosimilars Procurement 

Meaghan Smith is the executive director of the Biosimilars Forum. She previously served as a senior adviser and communications director at HHS during the Obama administration.

In this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.

Opinion: Biosimilars Offer Savings and Access for US Patients

Reverse switching occurs when patients transitioned to or initiated on a biosimilar are changed to an originator product, often because of a perceived failure in the biosimilar therapy.

Poll: Identify the Main Cause for Reverse Switching

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, reports on his citizen petition to the FDA to rationalize testing of biosimilars. 

Opinion: A Rational Approach to Establish Biosimilarity

Biosimilar manufacturers may encounter roadblocks in the months and years ahead, and generics manufacturers will find they've hit a ceiling, according to Adam Fein, PhD, CEO of the Drug Channels Institute.

Pharmacy Economist Describes Fork in the Road for Generics and Biosimilars

More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.

Medicines for Europe Panel Targets Inefficiencies, Need for Education

The pandemic interrupted health care for many patients and saddled health care institutions with high costs. How might biosimilars improve conditions?



Poll: Which of These Postpandemic Scenarios Is Most Likely?

With COVID-19 on the retreat, Coherus BioSciences sees the advantage wearing off for Amgen's pegfilgrastim injector kit. 

Coherus Aims to Chip Away at Onpro Dominance

The anatomy of an interchangeability switching study. 

Ophthalmology